# Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones

> **NCT00720031** · PHASE1,PHASE2 · COMPLETED · sponsor: **Nantes University Hospital** · enrollment: 16 (actual)

## Conditions studied

- Immunotherapy

## Interventions

- **BIOLOGICAL:** autologous Melan-A/MART-1 specific CTL clones

## Key facts

- **NCT ID:** NCT00720031
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-11
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2008-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00720031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00720031, "Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00720031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*